中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 药物化学研究室
Receptor dimerization - Rationale for the design of bivalent Ligands

文献类型：期刊论文

作者Zhang, Ao; Liu, Zhili; Kan, Ying
刊名CURRENT TOPICS IN MEDICINAL CHEMISTRY
出版日期2007
卷号7期号:4页码:343-345
关键词homodimer heterodimer monomer oligomerization bivalent ligand GPCR
ISSN号1568-0266
DOI10.2174/156802607779941279
文献子类Review
英文摘要Accumulating evidence has confirmed the existence and functional significance of GPCR and other types of receptor homodimers and heterodimers. However, many aspects of the biology and pharmacology of the dimerization process remain unclear. Several crystal structures of the dimerized proteins or protein-ligand complex have provided useful insights to the understanding of such process. As a common phenomenon of most receptors, homodimerization and heterodimerization have added a new dimension to characterize the receptor different from the traditional way, and open a new avenue to rational drug design and discovery.
WOS关键词PROTEIN-COUPLED RECEPTORS ; CELL-SURFACE ; CRYSTAL-STRUCTURE ; OPIOID RECEPTORS ; HETERODIMERIZATION ; OPIATE ; HOMODIMERIZATION ; HEXOPRENALINE ; ANTAGONISTS ; MOLECULES
WOS研究方向Pharmacology & Pharmacy
语种英语
WOS记录号WOS:000244703100002
出版者BENTHAM SCIENCE PUBL LTD
源URL[http://119.78.100.183/handle/2S10ELR8/273378]  
专题药物化学研究室
通讯作者Zhang, Ao
作者单位CAS, Shanghai Inst Mat Med, Modern Synthet Organ Chem Lab, Shanghai 201203, Peoples R China
推荐引用方式
GB/T 7714		 Zhang, Ao,Liu, Zhili,Kan, Ying. Receptor dimerization - Rationale for the design of bivalent Ligands[J]. CURRENT TOPICS IN MEDICINAL CHEMISTRY,2007,7(4):343-345.
APA Zhang, Ao,Liu, Zhili,&Kan, Ying.(2007).Receptor dimerization - Rationale for the design of bivalent Ligands.CURRENT TOPICS IN MEDICINAL CHEMISTRY,7(4),343-345.
MLA Zhang, Ao,et al."Receptor dimerization - Rationale for the design of bivalent Ligands".CURRENT TOPICS IN MEDICINAL CHEMISTRY 7.4(2007):343-345.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。